Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 15;13:10475–10487. doi: 10.2147/OTT.S253758

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Sun et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

MDM2 expression was elevated in DLBCL cells and tissues and high expression level of MDM2 was associated with poor outcome. (A) RT-qPCR analysis of MDM2 mRNA levels in DLBCL cells and PBMCs. (B) Western blot analysis of MDM2 protein expressions in DLBCL cells and PBMCs. (C and D) Immunofluorescence staining (× 630, scale bar, 10μm) for MDM2 protein expression in PBMCs and OCI-Ly3 or OCI-Ly10 cells. (E) The expression level of MDM2 in one normal and two representative cases of total 97 samples by using IHC (× 200; scale bar, 50 μm). (F) Kaplan-Meier OS analysis of 420 DLBCL patients with different MDM2 mRNA levels based on GSE10846 (n=420). Data were analyzed through R2 (http://r2.amc.nl). **P < 0.01; ***P < 0.001.

Abbreviations: DLBCL, diffuse large B-cell lymphoma; PBMCs, peripheral blood mononuclear cells; IHC, immunohistochemistry; OS, overall survival.